NCT02303392 - Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2015

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions

Prolymphocytic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia

Interventions

DRUG

Selinexor

Given PO

DRUG

Ibrutinib

Given PO

OTHER

Pharmacological Study

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (2)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

84112

Huntsman Cancer Institute, Salt Lake City